Clinical Trials Browser

Phase 1/2 × Not yet recruiting × NIH × Clear all

NCT06303193 2026-03-18

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Phase 1/2 Not yet recruiting

Classical hematologyMyeloid

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Bone Marrow Diseases, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT06694454 2026-03-18

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06991738 2026-03-18

177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

Phase 1/2 Not yet recruiting

Thyroid Neoplasms

NCT07328490 2026-03-18

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT07416188 2026-03-18

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Phase 1/2 Not yet recruiting

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, Recurrence, Central Nervous System Neoplasms

NCT07437963 2026-03-18

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Phase 1/2 Not yet recruiting

Neuroblastoma, Ganglioneuroblastoma

NCT07463807 2026-03-18

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Phase 1/2 Not yet recruiting

Multiple Myeloma